Anya Biopharm (奧孟亞), an innovative drug development firm, announced that its lead product, ANY002, has reached a critical milestone. The company’s licensing partner has officially completed GMP (Good Manufacturing Practice) manufacturing validation.

Significance of the Milestone:

• Commercial Scalability: Under the terms of the agreement, Anya Biopharm has collected the corresponding milestone payment. This validation confirms that the MIRA/JE technology platform is capable of commercial-scale production, securing the drug supply for upcoming clinical trials and global market entry.
• Strategy: CEO Siegfried Gschliesser noted that this achievement proves the scalability of their platform. Anya Biopharm continues its "asset-light, high-efficiency" strategy to develop next-generation oral peptide drugs targeting the massive diabetes and weight management markets (ANY002 and ANY004).

Resource: 授權夥伴完成GMP驗證，奧孟亞里程碑金入帳